Takashi Ohta
YOU?
Author Swipe
View article: 20P Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18)
20P Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18) Open
View article: Table 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Table 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Patient characteristics of four groups based on PPI use and the abundance of oral bacteria in the feces
View article: Supplementary Figure S1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
The association with concomitant drugs / lifestyle habits and alpha diversity with Shannon and Simpson index.
View article: Supplementary Figure S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Proportion of oral bacteria in patients with upper gastrointestinal cancers feces according to the presence or absence of a primary tumor by cancer type.
View article: Supplementary Figure S9 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S9 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
ALDEx2 analysis of the comparison of the fecal microbiome in patients with or without concomitant medication use before ICI treatment.
View article: Supplementary Figure S3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
The association with cancer types and alpha diversity with Shannon and Simpson index.
View article: Supplementary Figure S2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
The association with concomitant drugs / lifestyle habits and beta diversity.
View article: Supplementary Figure S7 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S7 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
The ALDEx2 analysis of flora according to PFS of ICI treatment.
View article: Supplementary Table S1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Table S1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Patient characteristics of PPI user and non-user in Cohort 1.
View article: Supplementary Table S3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Table S3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Patient characteristics of two groups based on the proportion of oral bacteria in feces in cohort 2.
View article: Figure 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Figure 3 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Relationship between ICI efficacy and bacterial flora/concomitant medication use. A, Kaplan–Meier plots of the PFS of patients treated with ICIs in the high ASV group and the low ASV group. The ASV cutoff was 206.0 (median). B,
View article: Data from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Data from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigate…
View article: Supplementary Figure S10 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S10 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
ICI efficacy between two categories of the proportion of oral bacteria in feces.
View article: Supplementary Figure S6 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S6 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Association of ICI efficacy with ASV based on treatment.
View article: Supplementary Table S2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Table S2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Concomitant drug usage in each cancer type in Cohort 2.
View article: Supplementary Table S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Table S4 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Multivariate analysis in PFS of ICIs in cohort 2.
View article: Supplementary Figure S11 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S11 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Validation with publicly data about oral bacteria and the efficacy of ICIs
View article: Table 2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Table 2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Patient characteristics in cohort 2
View article: Table 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Table 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Patient characteristics in cohort 1
View article: Supplementary Figure S8 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S8 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Association of ICI efficacy with concomitant medication use.
View article: Supplementary Figure S5 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Supplementary Figure S5 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Association of ICI efficacy with ASV based on treatment.
View article: Figure 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Figure 1 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
α diversity of gut microbiome according to clinical features and cancer types. A, Diagram depicting the selection of the MONSTAR-SCREEN cohorts. ECOG, Eastern Cooperative Oncology Group; PS, performance status. B, Definition …
View article: Figure 2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Figure 2 from Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Details of microbiome according to cancer types and PPI use in cohort 1. A, α diversity based on the observed number of ASVs according to cancer type, which was based on the analysis of at least five specimens obtained from patients…
View article: Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study
Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study Open
Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigate…
View article: Peri-Mitral Atrial Tachycardia Following Transcatheter Aortic Valve Replacement
Peri-Mitral Atrial Tachycardia Following Transcatheter Aortic Valve Replacement Open
View article: Supplementary Table 3 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Supplementary Table 3 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer Open
Alterations detected by ctDNA sequencing
View article: Supplementary Figure legend from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Supplementary Figure legend from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer Open
Supplementary Figure legend
View article: Supplementary Figure 1 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Supplementary Figure 1 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer Open
OS based on the Kaplan-Meier method for patients with FGFR2 amplification detected in tissue+ctDNA+ or tissue-ctDNA+ versus in tissue-ctDNA-
View article: Supplementary Table 2 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Supplementary Table 2 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer Open
Association between the FGFR2 amplification status and clinicopathological features
View article: Supplementary Figure 2 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Supplementary Figure 2 from Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer Open
Box plots show max VAF in the tissue+ctDNA+ and tissue-ctDNA+ groups